Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

TCGRx Launches The C-Ray Automatic Pill Counting Device In The Retail Pharmacy Market
TCGRx (TCG), an industry leader in automation and design services for pharmacy markets across the U.S., announced today the launch of the C-Ray Electronic Pill Counter in the retail pharmacy market.
generic viagra online
MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
News of the day
Increasing Age Of Mothers In Spain Leads To Rise In Mortality Rates
A new study examining the evolution of maternal mortality rates in Spain since 1996 shows a 17% increase in deaths. This trend is linked to the widespread increase in maternal age. The highest death rates are among foreign women and those who live in the province of Malaga.
Medical Devices

FDA Approves Generic Version Of Emergency Contraception Pills

FDA on Wednesday approved Watson Pharmaceuticals" generic version of the emergency contraceptive Plan B, the Wall Street Journal reports. The generic drug will be available without a prescription to women ages 18 and older on Aug. 24, when Duramed Pharmaceuticals" market exclusivity for Plan B expires (Kalish, Wall Street Journal, 6/25). The generic version will be available to women ages 17 and younger with a prescription, according to an FDA press release (FDA Web site, 6/24). Watson will market the generic version under the name Next Choice (AP/Washington Post, 6/24).A one-time use pack of the brand-name product, Plan B, currently costs $49.99 through the online retailer DrugStore.com. According to Bloomberg, generic drugs usually cost 30% to 80% less than brand-name versions (Larkin, Bloomberg, 6/24). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009